Log in Free sign up

Redhill Biopharma (RDHL) News and press releases

News

From Benzinga Pro

Stocks That Hit 52-Week Lows On Wednesday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Wednesday, 807 companies reached new 52-week lows.

12 Health Care Stocks Moving In Monday's Intraday Session

Intraday Update, Markets, Movers

RedHill Biopharma Announces $15M Registered Direct Offering With A Leading Healthcare Investor

News, Offerings

RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into a definitive agreement with a single leading

Stocks That Hit 52-Week Lows On Friday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Friday, 1043 companies hit new 52-week lows.

Stocks That Hit 52-Week Lows On Wednesday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

During Wednesday's trading, 435 companies set new 52-week lows.

26 Stocks Moving in Thursday's Pre-Market Session

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers Redbox Entertainment Inc. (NASDAQ: RDBX) rose 31.9% to $3.35 in pre-market trading after jumping around 25% on Wednesday.

RedHill Biopharma Says Opaganib Can Potentially Work Against COVID-19 Omicron Subvariants

Biotech, News, Penny Stocks, Health Care, Movers, Trading Ideas, General

RedHill Biopharma Announce Study Results Showing Opaganib Was Observed To Have In Vitro Efficacy Against Omicron SARS-CoV-2 Variant

Biotech, General

Oral opaganib's reported potent in vitro activity against Omicron adds to previously observed inhibition of Delta and other SARS-CoV-2 variants of concern that cause COVID-19; Testing conducted by The University of

64 Biggest Movers From Yesterday

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers Kidpik Corp. (NASDAQ: PIK) shares surged 158.2% to settle at $4.75 on Thursday after the company announced a partnership with The Walt Disney Co.

Redhill Biopharma: Q4 Earnings Insights

Redhill Biopharma (NASDAQ:RDHL) reported its Q4 earnings results on Thursday, March 17, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Redhill Biopharma Q4 Sales $22.10M Miss $24.08M Estimate

Redhill Biopharma (NASDAQ:RDHL) reported quarterly sales of $22.10 million which missed the analyst consensus estimate of $24.08 million by 8.22 percent. This is a 2.98 percent increase over sales of $21.46 million the

Earnings Scheduled For March 17, 2022

Earnings, News, Pre-Market Outlook, Markets

Companies Reporting Before The Bell • TransGlobe Energy (NASDAQ:TGA) is estimated to report earnings for its fourth quarter.

Redhill Biopharma's Earnings: A Preview

Redhill Biopharma (NASDAQ:RDHL) is set to give its latest quarterly earnings report on Thursday, 2022-03-17. Here's what investors need to know before the announcement. Analysts estimate that Redhill Biopharma will report an earnings per share (EPS) of $-0.33.

RedHill, Kukbo Ink Oral Opaganib Licensing Pact For COVID-19 In South Korea

Biotech, News, Penny Stocks, Health Care, Contracts, Movers, Trading Ideas, General

Stocks That Hit 52-Week Lows On Tuesday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

During Tuesday's session, 454 stocks hit new 52-week lows.

RedHill Biopharma Reports License Deal With Kukbo For Oral Opaganib For COVID-19 In South Korea; Co. To Receive Upfront Payment Of $1.5M, Eligible For Up To $5.6M In Milestone Payments

Biotech, News, FDA, General

RedHill to receive $1.5 million upfront and is eligible for up to $5.6 million in milestone payments in addition to royalties on net sales from Kukbo Opaganib's Phase 2/3 clinical data shows improved viral RNA

Stocks That Hit 52-Week Lows On Tuesday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

Tuesday's session saw 729 companies set new 52-week lows.

Stocks That Hit 52-Week Lows On Monday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Monday, 524 stocks hit new 52-week lows.

Stocks That Hit 52-Week Lows On Friday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Friday, 368 stocks hit new 52-week lows.

RedHill Biopharma's Upamostat Shows 100% Efficacy In Non-Hospitalized COVID-19 Patients

Biotech, News, Penny Stocks, Health Care, General

RedHill Biopharma Ltd (NASDAQ: RDHL) has

Press releases

From Benzinga Pro

RedHill Presents New Talicia® Data Analyses at DDW 2022

Talicia's efficacy and safety profile evaluated in patients with H. pylori infection and diabetes mellitus, a large and challenging patient population associated with sub-optimal outcomes with clarithromycin-based H.

RedHill Biopharma Announces $15 Million Registered Direct Offering with a Leading Healthcare Investor

Offerings, Press Releases

TEL AVIV, Israel and RALEIGH, N.C, May 9, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered

RedHill Reports Potent Inhibition of Omicron with Oral COVID-19 Drug Candidate Opaganib In Vitro

- Oral opaganib's reported potent in vitro activity against Omicron adds to previously observed inhibition of Delta and other SARS-CoV-2 variants of concern that cause COVID-19; Testing conducted by The University of

RedHill Biopharma Ltd Announces Potent Omicron Inhibition with RedHill's Opaganib

News, Press Releases

Oral opaganib's reported potent in vitro activity against Omicron adds to previously observed inhibition of Delta and other SARS-CoV-2 variants of concern that cause COVID-19; Testing conducted by The University of Hong

Biopharma Stocks Targeting Crohn's Disease In $13.7 Billion Market (STAB, ARNA, GILD and RDHL)

News, Press Releases

Biopharmaceutical stocks are targeting Crohn’s Disease in developing drugs in 2022. Research finds that this is a $13.7 billion market ripe for sector stock catalysts such as profit and dividends. CATALYSTS

RedHill Biopharma to Host Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights Webcast on March 17, 2022

TEL AVIV, Israel and RALEIGH, NC, March 10, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will

RedHill Announces Positive Phase 2 Study Results with Oral RHB-107 in Non-Hospitalized COVID-19

TEL AVIV, Israel and RALEIGH, N.C., March 1, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced